<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797742</url>
  </required_header>
  <id_info>
    <org_study_id>HF201801</org_study_id>
    <nct_id>NCT03797742</nct_id>
  </id_info>
  <brief_title>A Clinical Follow-up Study of Heart Failure Patients.</brief_title>
  <official_title>A Clinical Follow-up Study of Heart Failure Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF), a current worldwide pandemic with an unacceptable high level of morbidity
      and mortality, brings an enormous medical and societal burden. Chronic HF is characterized by
      progressive alteration of cardiac structure and function. But the molecular mechanism of
      these alterations is still not well-established and needs to be discussed further. HF is a
      highly heterogeneous disease that can be caused by a multiple of diseases. Dilated
      cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) are the main causes of this syndrome.
      Although HF is the common manifestation of DCM and ICM, the etiology and pathogenesis are
      different. Understanding the different pathophysiological mechanisms will contribute to the
      prevention and individualized therapy of heart failure. Therefore, this study aims to
      observation the different characteristics of the molecular biology and clinical courses in
      DCM and ICM patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>one year after enrolled</time_frame>
    <description>NYHA cardiac functional class</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>one year after enrolled</time_frame>
    <description>All-cause mortality during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospitalization for cardiac causes</measure>
    <time_frame>one year after enrolled</time_frame>
    <description>hospitalization for cardiac causes during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular end-diastolic dimension(LVEDD) dilates.</measure>
    <time_frame>one year after enrolled</time_frame>
    <description>left ventricular structure changes:left ventricular end-diastolic dimension(LVEDD) dilates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular ejection fraction reduces</measure>
    <time_frame>one year after enrolled</time_frame>
    <description>left ventricular function changes:left ventricular ejection fraction reduces</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>NC</arm_group_label>
    <description>Patients without heart failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCM</arm_group_label>
    <description>Dilated cardiomyopathy patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICM</arm_group_label>
    <description>Ischemic cardiomyopathy patients.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum; Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The inpatient in the department of cardiology of Zhongshan Hospital, Fudan University will
        be selected.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF≤ 55%

          -  enlarged left ventricular end-diastolic dimension

          -  ICM group: with history of MI or revascularization; ≥ 75% stenosis of LM or proximal
             LAD; ≥ 75% stenosis of two or more epicardial vessels.

          -  symptomatic heart failure

        Exclusion Criteria:

          -  Known malignant tumour diseases

          -  Pregnancy or lactation period；

          -  Investigators think not suitable to participate in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhangwei Chen</last_name>
    <phone>+86 021 64041990</phone>
    <email>chen.zhangwei@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhangwei Chen</last_name>
      <phone>+8602164041990</phone>
      <email>chen.zhangwei@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

